Pulmonary Hypertension | Norton Healthcare

Indication: Pulmonary Hypertension

A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients with Pulmonary Hypertension due to Chronic Obstructive Pulmonary Disease (PH-COPD)

Sub-indication: Pulmonary Hypertension

Drug Study

Principal Investigator: John McConnell, M.D.
Norton Pulmonary Specialists

Sponsor: UNITED THERAPEUTICS CORPORATION

Learn more at ClinicalTrials.gov

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.